{"slideshow_credits": null, "snippet": "Longer treatment with Herceptin added no benefit while a shorter treatment was not as favorable, according to the results of two closely watched studies.", "abstract": "Two studies by Roche and French National Cancer Institute find neither shorter nor longer duration of treatment with Roche's breast cancer drug Herceptin is better at staving off a recurrence of cancer than the current standard of one year.", "section_name": "Business Day", "print_page": "4", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/10/02/business/current-length-of-herceptin-treatment-is-supported-by-studies.html", "lead_paragraph": "Longer treatment with Herceptin added no benefit while a shorter treatment was not as favorable, according to the results of two closely watched studies.", "headline": {"seo": "Current Length of Herceptin Treatment Is Supported by Studies", "main": "Studies Back Length of Herceptin Cancer Treatment", "print_headline": "Studies Back Length of Herceptin Cancer Treatment"}, "_id": "53fb735b38f0d84b3469fd85", "word_count": "599", "multimedia": [], "pub_date": "2012-10-02T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Roche Holding A G", "name": "organizations", "is_major": "Y", "rank": "1"}, {"value": "Herceptin (Drug)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Breast Cancer", "name": "subject", "is_major": "Y", "rank": "3"}], "blog": [], "subsection_name": null, "type_of_material": "News"}